Robert L. Ferris, MD, PhD | Authors

November 29, 2022

Advances in thyroid cancer to date hold promise for other orphan cancers with analogous alterations, on which we might bring to bear agents that will have similar effects.

October 19, 2022

The oncology community has enjoyed success to a large degree through the existing NIH and NCI mechanisms. Will they ask how can they work with us in a concerted fashion to benefit new discoveries, novel translation in well-designed clinical trials, and eventual development of exciting, more effective cancer therapies for patients?

September 26, 2022

Emerging from a 2-year pandemic, the work-from-home revolution has led to the migration of staff to the pharmaceutical industry or contract research organizations.

July 22, 2022

Harnessing existing and otherwise safe antibody-targeting strategies and combining them with chemotherapy or other bioactive compounds or as a bispecific dual antibody moiety are an exciting strategy of protein engineering that is emerging and coming into its own in oncology.

May 16, 2022

There is a role for these overlapping entities—guidelines and pathways—and each permits flexibility for the oncologist for available treatment options in the level and quality of data.

April 07, 2022

Using combination treatments in the concurrent setting with chemotherapy, radiation therapy, or small molecule oncogene and pathway inhibitors may yield positive data in one setting but not another.